The presence of genomic imbalances is associated with poor outcome in patients with Burkitt Lymphoma treated with dose-intensive chemotherapy including rituximab

The presence of genomic imbalances is associated with poor outcome in patients with Burkitt Lymphoma treated with dose-intensive chemotherapy including rituximab

Forero-Castro M (2016), British Journal of Haematology Link to abstract                                                   

This study aimed to identify genomic changes that could predict treatment-response to chemotherapy and rituximab for Burkitt lymphoma. Forty Burkitt lymphoma patients were analyzed using array-based comparative genomic hybridization, and TP53, TCF3, ID3 and GNA13 mutations were assessed by next generation sequencing. Losses of 11q, 13q, 15q or 17p were associated with poor response to rituximab treatment, shortened PFS and OS. TP53 alterations were associated with shorter PFS and TCF3 alterations were associated with shorter OS.


* Genetic studies could potentially be used for risk stratification of Burkitt lymphoma patients.